George Courcoubetis

Feb 14, 2024 | nature.com | George Courcoubetis |Peter J. Kuhn |Peter Kühn |Emmeline Lin

AbstractPancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of less than 10% due to its late diagnosis, rapid metastasis, and chemotherapeutic resistance. For a small proportion (10–20%) of early-stage patients however, surgical resection of the pancreatic tumor offers the best chance for survival but the effect of surgery on disease dissemination is unknown.